Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Summary: Background: In recent months, Omicron variants of SARS-CoV-2 have become dominant in many regions of the world, and case numbers with Omicron subvariants BA.1 and BA.2 continue to increase. Due to numerous mutations in the spike protein, the efficacy of currently available vaccines, which...

Full description

Bibliographic Details
Main Authors: Alexander Wilhelm, Marek Widera, Katharina Grikscheit, Tuna Toptan, Barbara Schenk, Christiane Pallas, Melinda Metzler, Niko Kohmer, Sebastian Hoehl, Rolf Marschalek, Eva Herrmann, Fabian A. Helfritz, Timo Wolf, Udo Goetsch, Sandra Ciesek
Format: Article
Language:English
Published: Elsevier 2022-08-01
Series:EBioMedicine
Subjects:
SARS-CoV-2
Omicron
BA.1
BA.2
Waning Immunity
Sotrovimab
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396422003395

Internet

http://www.sciencedirect.com/science/article/pii/S2352396422003395

Similar Items